This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hisaeda, H.
Right arrow Articles by Kaslow, D. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hisaeda, H.
Right arrow Articles by Kaslow, D. C.

 Previous Article  |  Next Article 

Infection and Immunity, December 2000, p. 6618-6623, Vol. 68, No. 12
0019-9567/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Antibodies to Malaria Vaccine Candidates Pvs25 and Pvs28 Completely Block the Ability of Plasmodium vivax To Infect Mosquitoes

Hajime Hisaeda,1,2 Anthony W. Stowers,1,* Takafumi Tsuboi,3 William E. Collins,4 Jetsumon S. Sattabongkot,5 Natavadee Suwanabun,5 Motomi Torii,3 and David C. Kaslow1,dagger

Malaria Vaccine Development Unit, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland 208521; Department of Parasitology and Immunology, University of Tokushima School of Medicine, Tokushima 770-8503,2 and Department of Molecular Parasitology, Ehime University School of Medicine, Shigenobu-cho, Ehime 791-0295,3 Japan; Division of Parasitic Diseases and Animal Resources Branch, Scientific Resources Program, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Chamblee, Georgia 303414; and Department of Entomology, Armed Forces Research Institute of Medical Sciences, Phayathai, Bangkok 10400, Thailand5

Received 21 July 2000/Returned for modification 6 September 2000/Accepted 16 September 2000

Transmission-blocking vaccines are one strategy for controlling malaria, whereby sexual-stage parasites are inhibited from infecting mosquitoes by human antibodies. To evaluate whether the recently cloned Plasmodium vivax proteins Pvs25 and Pvs28 are candidates for a transmission-blocking vaccine, the molecules were expressed in yeast as secreted recombinant proteins. Mice vaccinated with these proteins adsorbed to aluminum hydroxide developed strong antibody responses against the immunogens, although for Pvs28, this response was genetically restricted. Antisera against both recombinant Pvs25 and Pvs28 recognized the corresponding molecules expressed by cultured sexual-stage parasites isolated from patients with P. vivax malaria. The development of malaria parasites in mosquitoes was completely inhibited when these antisera were ingested with the infected blood meal. Pvs25 and Pvs28, expressed in Saccharomyces cerevisiae, are as yet the only fully characterized transmission-blocking vaccine candidates against P. vivax that induce such a potent antiparasite response.

* Corresponding author. Mailing address: Malaria Vaccine Development Unit, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 12441 Parklawn Dr., Rockville, MD 20852. Phone: (301) 435-2968. Fax: (301) 435-6725. E-mail: astowers{at}niaid.nih.gov.

dagger Present address: Viral and Vaccine Research, Merck Research Labs, West Point, PA 19486.

Infection and Immunity, December 2000, p. 6618-6623, Vol. 68, No. 12
0019-9567/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Collins, W. E., Sullivan, J. S., Strobert, E., Galland, G. G., Williams, A., Nace, D., Williams, T., Barnwell, J. W. (2009). Studies on the Salvador I Strain of Plasmodium vivax in Non-human Primates and Anopheline Mosquitoes. Am J Trop Med Hyg 80: 228-235 [Abstract] [Full Text]  
  • Saxena, A. K., Wu, Y., Garboczi, D. N. (2007). Plasmodium P25 and P28 Surface Proteins: Potential Transmission-Blocking Vaccines. Eukaryot Cell 6: 1260-1265 [Full Text]  
  • Arakawa, T., Komesu, A., Otsuki, H., Sattabongkot, J., Udomsangpetch, R., Matsumoto, Y., Tsuji, N., Wu, Y., Torii, M., Tsuboi, T. (2005). Nasal Immunization with a Malaria Transmission-Blocking Vaccine Candidate, Pfs25, Induces Complete Protective Immunity in Mice against Field Isolates of Plasmodium falciparum. Infect. Immun. 73: 7375-7380 [Abstract] [Full Text]  
  • AREVALO-HERRERA, M., SOLARTE, Y., YASNOT, M. F., CASTELLANOS, A., RINCON, A., SAUL, A., MU, J., LONG, C., MILLER, L., HERRERA, S. (2005). INDUCTION OF TRANSMISSION-BLOCKING IMMUNITY IN AOTUS MONKEYS BY VACCINATION WITH A PLASMODIUM VIVAX CLINICAL GRADE PVS25 RECOMBINANT PROTEIN. Am J Trop Med Hyg 73: 32-37 [Abstract] [Full Text]  
  • AREVALO-HERRERA, M., SOLARTE, Y., ZAMORA, F., MENDEZ, F., YASNOT, M. F., ROCHA, L., LONG, C., MILLER, L. H., HERRERA, S. (2005). PLASMODIUM VIVAX: TRANSMISSION-BLOCKING IMMUNITY IN A MALARIA-ENDEMIC AREA OF COLOMBIA. Am J Trop Med Hyg 73: 38-43 [Abstract] [Full Text]  
  • Darko, C. A., Angov, E., Collins, W. E., Bergmann-Leitner, E. S., Girouard, A. S., Hitt, S. L., McBride, J. S., Diggs, C. L., Holder, A. A., Long, C. A., Barnwell, J. W., Lyon, J. A. (2005). The Clinical-Grade 42-Kilodalton Fragment of Merozoite Surface Protein 1 of Plasmodium falciparum Strain FVO Expressed in Escherichia coli Protects Aotus nancymai against Challenge with Homologous Erythrocytic-Stage Parasites. Infect. Immun. 73: 287-297 [Abstract] [Full Text]  
  • Li, F., Templeton, T. J., Popov, V., Comer, J. E., Tsuboi, T., Torii, M., Vinetz, J. M. (2004). Plasmodium Ookinete-secreted Proteins Secreted through a Common Micronemal Pathway Are Targets of Blocking Malaria Transmission. J. Biol. Chem. 279: 26635-26644 [Abstract] [Full Text]  
  • Dinglasan, R. R., Fields, I., Shahabuddin, M., Azad, A. F., Sacci, J. B. Jr. (2003). Monoclonal Antibody MG96 Completely Blocks Plasmodium yoelii Development in Anopheles stephensi. Infect. Immun. 71: 6995-7001 [Abstract] [Full Text]  
  • SATTABONGKOT, J., TSUBOI, T., HISAEDA, H., TACHIBANA, M., SUWANABUN, N., RUNGRUANG, T., CAO, Y.-M., STOWERS, A. W., SIRICHAISINTHOP, J., COLEMAN, R. E., TORII, M. (2003). BLOCKING OF TRANSMISSION TO MOSQUITOES BY ANTIBODY TO PLASMODIUM VIVAX MALARIA VACCINE CANDIDATES PVS25 AND PVS28 DESPITE ANTIGENIC POLYMORPHISM IN FIELD ISOLATES. Am J Trop Med Hyg 69: 536-541 [Abstract] [Full Text]  
  • Stowers, A. W., Kennedy, M. C., Keegan, B. P., Saul, A., Long, C. A., Miller, L. H. (2002). Vaccination of Monkeys with Recombinant Plasmodium falciparum Apical Membrane Antigen 1 Confers Protection against Blood-Stage Malaria. Infect. Immun. 70: 6961-6967 [Abstract] [Full Text]  
  • Dutta, S., Ware, L. A., Barbosa, A., Ockenhouse, C. F., Lanar, D. E. (2001). Purification, Characterization, and Immunogenicity of a Disulfide Cross-Linked Plasmodium vivax Vaccine Candidate Antigen, Merozoite Surface Protein 1, Expressed in Escherichia coli. Infect. Immun. 69: 5464-5470 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»